Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 8/20 | 0.57 |
| ▸ | DRD5 | P21918 | 7/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620839 | 1.00 | DRD1 (0.57) | DRD1DRD5MAOATP53TSHR | |
| Bromide SCHEMBL7537739 | 0.99 | DRD1 (0.56) | DRD1DRD5MAOATP53TSHR | |
| SCHEMBL8747125 | 0.96 | DRD1 (0.55) | DRD1DRD5MAOATP53TSHR | |
| SCHEMBL8747279 | 0.96 | DRD1 (0.55) | DRD1DRD5MAOATP53TSHR | |
| Bromide SCHEMBL8747356 | 0.95 | DRD1 (0.54) | DRD1DRD5MAOATP53TSHR | |
| Hydrochloric Acid SCHEMBL8972145 | 0.95 | DRD1 (0.54) | DRD1DRD5MAOATP53TSHR | |
| SCHEMBL8747305 | 0.91 | DRD1 (0.54) | DRD1DRD5MAOATP53TSHR | |
| SCHEMBL8747089 | 0.90 | DRD1 (0.51) | DRD1DRD5MAOATP53TSHR | |
| Bromide SCHEMBL8747136 | 0.90 | DRD1 (0.53) | DRD1DRD5MAOATP53TSHR | |
| SCHEMBL8747176 | 0.89 | DRD1 (0.51) | DRD1DRD5MAOATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137767-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2002-09-26 | — | — | US | claimed |
| US-20010053786-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2001-12-20 | — | — | US | claimed |
| JP-2642244-B2 | — | — | 1997-08-20 | — | — | JP | claimed |
| EP-0618900-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1997-03-12 | — | — | EP | claimed |
| US-5519034-A | ANALGESICS | THE BOOTS COMPANY PLC (GB) | 1996-05-21 | — | — | US | claimed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | claimed |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | EMALEX BIOSCIENCES INC (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3057595-B1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | EMALEX BIOSCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-9949983-B2 | Fused benzazepines for treatment of stuttering | PSYADON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals ,Inc. | 2016-09-22 | — | — | US | disclosed |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | HORIZON TECHNOLOGY FINANCE CORPORATION | 2015-06-18 | — | — | US | disclosed |
| WO-2015058053-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | PSYADON PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20020137767-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2002-09-26 | — | — | US | disclosed |
| US-20020137767-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2002-09-26 | — | — | US | disclosed |
| US-20010053786-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| US-20010053786-A1 | Methods for treating addictive disorders | HEAL DAVID JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0618900-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5519034-A | ANALGESICS | THE BOOTS COMPANY PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| EP-0618900-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053786-A1 | Methods for treating addictive disorders | DRD2, OPRD1, DRD3 | DRD1 9/4885DRD5 16/4885MAOA 251/4885 |
| US-20020137767-A1 | Methods for treating addictive disorders | DRD2, OPRD1, DRD3 | DRD1 9/4885DRD5 16/4885MAOA 251/4885 |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | TACR1, AVPR1A, AVPR1B | DRD1 28/4885DRD5 40/4885MAOA 1890/4885 |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | COMT, SLC6A3, HTR5A | DRD1 40/4885DRD5 46/4885MAOA 298/4885 |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | COMT, SLC6A3, HTR3A | DRD1 30/4885DRD5 39/4885MAOA 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.